To include your compound in the COVID-19 Resource Center, submit it here.

FDA wants more Arcoxia data

Merck (MRK) received an FDA approvable letter for its

Read the full 91 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE